News | February 10, 2025
Wockhardt posts Q3 net profit at Rs. 20 Cr
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
He has over 23 years of experience across sectors
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
TFOS is indicated for the treatment of pulmonary arterial hypertension
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Plans underway to expand screening capacity by 50% for greater accessibility
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Branded formulation business continues to perform well across domestic and export markets
Cancer cases in India estimated to reach 1.57 million in 2025
Subscribe To Our Newsletter & Stay Updated
